Anti-claudin-2 monoclonal antibody

Patent metadata

Field	Value
Publication number	US-11078271-B2
Application number	US-201716473413-A
Country	US
Kind code	B2
Filing date	Dec 25, 2017
Priority date	Dec 28, 2016
Publication date	Aug 3, 2021
Grant date	Aug 3, 2021

Abstract

An object of the present invention is to provide a monoclonal antibody that recognizes an extracellular region of Claudin-2. A monoclonal antibody that specifically binds to an extracellular region of Claudin-2.

First claim

The invention claimed is:

1. A monoclonal antibody that specifically binds to an extracellular region of Claudin-2, the monoclonal antibody comprising:
the heavy-chain variable region comprising the amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 13 and the light-chain variable region comprising the amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 15;
and wherein the heavy-chain variable region comprising: heavy-chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, heavy-chain CDR2 comprising the amino acid sequence of SEQ ID NO: 3, and heavy-chain CDR3 comprising the amino acid sequence of SEQ ID NO: 5; and wherein the light-chain variable region comprising: light-chain CDR1 comprising the amino acid sequence of SEQ ID NO: 7, light-chain CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and light-chain CDR3 comprising the amino acid sequence of SEQ ID NO: 11.

2. The monoclonal antibody according to claim 1 , wherein the monoclonal antibody recognizes a three-dimensional structure of the extracellular region of Claudin-2.

3. The monoclonal antibody according to claim 1 , wherein the extracellular region is an extracellular region first loop of Claudin-2.

4. The monoclonal antibody according to claim 1 , wherein the monoclonal antibody has a structure of Fab, Fab′, (Fab′) 2 , Fv, scFv, or a combination thereof.

5. The monoclonal antibody according to claim 1 , wherein the monoclonal antibody is a chimeric antibody or a humanized antibody.

6. A pharmaceutical composition comprising the monoclonal antibody according to claim 1 .

7. The pharmaceutical composition according to claim 6 , wherein the pharmaceutical composition is used for the treatment of inflammatory bowel disease.

8. The pharmaceutical composition according to claim 6 , wherein the pharmaceutical composition is used for the treatment of cancer.

9. A monoclonal antibody that specifically binds to an extracellular region of Claudin-2, the monoclonal antibody comprising:
the heavy-chain variable region comprising the amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 14 and the light-chain variable region comprising the amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 16; and wherein the heavy-chain variable region comprising: heavy-chain CDR1 comprising the amino acid sequence of SEQ ID NO: 2, heavy-chain CDR2 comprising the amino acid sequence of SEQ ID NO: 4, and heavy-chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6; and wherein the light-chain variable region comprising: light-chain CDR1 comprising the amino acid sequence of SEQ ID NO: 8, light-chain CDR2 comprising the amino acid sequence of SEQ ID NO: 10, and light-chain CDR3 comprising the amino acid of SEQ ID NO: 12.

10. The monoclonal antibody according to claim 9 , wherein the monoclonal antibody recognizes a three-dimensional structure of the extracellular region of Claudin-2.

11. The monoclonal antibody according to claim 9 , wherein the extracellular region is an extracellular region first loop of Claudin-2.

12. The monoclonal antibody according to claim 9 , wherein the monoclonal antibody has a structure of Fab, Fab′, (Fab′) 2 , Fv, scFv, or a combination thereof.

13. The monoclonal antibody according to claim 9 , wherein the monoclonal antibody is a chimeric antibody or a humanized antibody.

14. A pharmaceutical composition comprising the monoclonal antibody according to claim 9 .

15. The pharmaceutical composition according to claim 14 , wherein the pharmaceutical composition is used for the treatment of inflammatory bowel disease.

16. The pharmaceutical composition according to claim 14 , wherein the pharmaceutical composition is used for the treatment of cancer.

Assignees

• Univ Osaka
• Japan As Represented By Director General Of Nat Institute Of Health Sciences

Inventors

• Kondoh Masuo
• Yagi Kiyohito
• Watari Akihiro
• Fukasawa Masayoshi
• Tada Minoru
• Kunisawa Jun

Classifications

• C07K2317/77

  Internalization into the cell · CPC title

• C07K2317/734

  Complement-dependent cytotoxicity [CDC] · CPC title

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/30

  characterized by aspects of specificity or valency · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title